Rapt Therapeutics Inc (RAPT)

Ticker: RAPT Exchange: NMS


Loading...
Purchase Sale Planned purchase Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Rapt Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Top insiders
Trades
Planned sale 5 Jan 2024
Value US$3,479,263.76 | Price 226.91 | Shares 52,673 (+1.3%)
Proposed sale 5 Jan 2024
Value US$1,783,186.28 | Price 488.02 | Shares 43,599
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value
Number of shares Price Value Details
2024-01-08 2024-01-05 PlS Planned sale

CHIEF SCIENTIFIC OFFICER

Officer
52,673 +1.3%
226.91
US$3,479,264
52,673 +1.3% 226.91 US$3,479,264
2024-01-05 2024-01-05 PrS Proposed sale

Officer

Officer
43,599
488.02
US$1,783,186
43,599 488.02 US$1,783,186
2023-12-22 2023-12-21 PlS Planned sale

Chief Medical Officer

Officer
35,595 +20.6%
453.18
US$373,175
35,595 +20.6% 453.18 US$373,175
2023-12-21 2023-12-21 PrS Proposed sale

Officer

Officer
2,500
21.68
US$54,200
2,500 21.68 US$54,200
2023-11-29 2023-11-28 PlS Planned sale

Chief Medical Officer

Officer
1,500 -7.9%
13.72
US$20,580
1,500 -7.9% 13.72 US$20,580
2023-11-28 2023-11-28 PrS Proposed sale

Officer

Officer
1,500
13.72
US$20,580
1,500 13.72 US$20,580
2023-10-04 2023-10-03 PlS Planned sale

Chief Medical Officer

Officer
2,500 -11.7%
15.77
US$39,425
2,500 -11.7% 15.77 US$39,425
2023-10-03 2023-10-03 PrS Proposed sale

Officer

Officer
2,500
15.77
US$39,425
2,500 15.77 US$39,425
2023-08-22 2023-08-18 PlS Planned sale

Chief Medical Officer

Officer
2,500 -10.5%
18.92
US$47,300
2,500 -10.5% 18.92 US$47,300
2023-08-18 2023-08-18 PrS Proposed sale

Officer

Officer
2,500
18.92
US$47,300
2,500 18.92 US$47,300
2023-04-20 2023-04-19 PlS Planned sale

Chief Medical Officer

Officer
5,000 -19.2%
18.88
US$94,400
5,000 -19.2% 18.88 US$94,400
2023-04-19 2023-04-19 PrS Proposed sale

Officer

Officer
5,000
18.88
US$94,400
5,000 18.88 US$94,400
2023-03-15 2023-03-14 B Purchase Non-Executive Director
2,500 +62.5%
20.05
US$50,125
2,500 +62.5% 20.05 US$50,125
2023-03-15 2023-03-14 B Purchase Non-Executive Director
600 +4.2%
19.95
US$11,970
600 +4.2% 19.95 US$11,970
2023-03-15 2023-03-14 B Purchase Non-Executive Director
400 +2.9%
18.48
US$7,392
400 +2.9% 18.48 US$7,392
2023-03-15 2023-03-14 B Purchase Non-Executive Director
1,500 +12.1%
18.75
US$28,125
1,500 +12.1% 18.75 US$28,125
2023-03-13 2023-03-07 PlS Planned sale

Chief Medical Officer

Officer
5,000 -16.4%
29.62
US$148,100
5,000 -16.4% 29.62 US$148,100
2023-01-26 2023-01-24 PlS Planned sale

Chief Medical Officer

Officer
5,000 -14.3%
30.00
US$150,000
5,000 -14.3% 30.00 US$150,000
2023-01-20 2023-01-19 PlS Planned sale

Chief Medical Officer

Officer
5,000 -12.5%
25.56
US$127,800
5,000 -12.5% 25.56 US$127,800
2023-01-09 2023-01-05 S Sale

Chief Scientific Officer

Officer
742 -3.7%
21.97
US$16,299
742 -3.7% 21.97 US$16,299
2022-12-30 2022-12-29 PlS Planned sale

Chief Medical Officer

Officer
5,000 -11.7%
18.03
US$90,150
5,000 -11.7% 18.03 US$90,150
2022-11-29 2022-11-28 PlS Planned sale

Chief Medical Officer

Officer
5,000 -10.5%
17.87
US$89,350
5,000 -10.5% 17.87 US$89,350
2022-11-03 2022-11-02 PlS Planned sale

Chief Medical Officer

Officer
5,000 -9.5%
22.32
US$111,600
5,000 -9.5% 22.32 US$111,600
2022-10-14 2022-10-13 PlS Planned sale

Chief Medical Officer

Officer
2,000 -3.7%
21.52
US$43,040
2,000 -3.7% 21.52 US$43,040
2022-08-31 2022-08-30 PlS Planned sale

Chief Medical Officer

Officer
2,500 -4.5%
28.13
US$70,325
2,500 -4.5% 28.13 US$70,325
2022-07-13 2022-07-11 S Sale

Chief Medical Officer

Officer
2,000 -3.7%
19.95
US$39,900
2,000 -3.7% 19.95 US$39,900
2022-05-27 2022-05-25 B Purchase Large shareholder
63 +0.1%
12.45
US$785
63 +0.1% 12.45 US$785
2022-05-27 2022-05-25 B Purchase Large shareholder
1,837 +0.1%
12.45
US$22,880
1,837 +0.1% 12.45 US$22,880
2022-05-27 2022-05-25 B Purchase Large shareholder
63 +0.1%
12.45
US$785
63 +0.1% 12.45 US$785
2022-05-27 2022-05-25 B Purchase Large shareholder
1,837 +0.1%
12.45
US$22,880
1,837 +0.1% 12.45 US$22,880
2022-05-25 2022-05-24 B Purchase Large shareholder
538 +1.3%
12.00
US$6,457
538 +1.3% 12.00 US$6,457
2022-05-25 2022-05-24 B Purchase Large shareholder
15,776 +1.3%
12.00
US$189,345
15,776 +1.3% 12.00 US$189,345
2022-05-25 2022-05-24 B Purchase Large shareholder
538 +1.3%
12.00
US$6,457
538 +1.3% 12.00 US$6,457
2022-05-25 2022-05-24 B Purchase Large shareholder
15,776 +1.3%
12.00
US$189,345
15,776 +1.3% 12.00 US$189,345
2022-05-25 2022-05-23 B Purchase Large shareholder
338 +0.8%
12.50
US$4,225
338 +0.8% 12.50 US$4,225
2022-05-25 2022-05-23 B Purchase Large shareholder
9,898 +0.8%
12.50
US$123,718
9,898 +0.8% 12.50 US$123,718
2022-05-25 2022-05-23 B Purchase Large shareholder
338 +0.8%
12.50
US$4,225
338 +0.8% 12.50 US$4,225
2022-05-25 2022-05-23 B Purchase Large shareholder
9,898 +0.8%
12.50
US$123,718
9,898 +0.8% 12.50 US$123,718
2022-05-12 2022-05-10 B Purchase Large shareholder
41,250 +inf%
10.67
US$440,199
41,250 +inf% 10.67 US$440,199
2022-05-12 2022-05-10 B Purchase Large shareholder
1,208,750 +inf%
10.67
US$12,899,176
1,208,750 +inf% 10.67 US$12,899,176
2022-05-12 2022-05-10 B Purchase Non-Executive Director
400 +11.1%
10.62
US$4,248
400 +11.1% 10.62 US$4,248
2022-05-12 2022-05-10 B Purchase Non-Executive Director
600 +20.0%
10.49
US$6,294
600 +20.0% 10.49 US$6,294
2022-05-12 2022-05-10 B Purchase Non-Executive Director
1,000 +50.0%
10.51
US$10,510
1,000 +50.0% 10.51 US$10,510
2022-05-12 2022-05-10 B Purchase Non-Executive Director
500 +38.5%
11.30
US$5,650
500 +38.5% 11.30 US$5,650
2022-05-12 2022-05-10 B Purchase Non-Executive Director
2,500 +22.1%
11.80
US$29,500
2,500 +22.1% 11.80 US$29,500
2022-05-12 2022-05-10 B Purchase Non-Executive Director
2,000 +21.5%
10.54
US$21,080
2,000 +21.5% 10.54 US$21,080
2022-05-12 2022-05-10 PP Planned purchase

Chief Financial Officer

Officer
5,000 +98.3%
10.53
US$52,650
5,000 +98.3% 10.53 US$52,650
2022-05-12 2022-05-10 B Purchase Large shareholder
41,250 +inf%
10.67
US$440,199
41,250 +inf% 10.67 US$440,199
2022-05-12 2022-05-10 B Purchase Large shareholder
1,208,750 +inf%
10.67
US$12,899,176
1,208,750 +inf% 10.67 US$12,899,176
2022-05-05 2022-05-04 PlS Planned sale

Chief Scientific Officer

Officer
720 -3.5%
15.05
US$10,836
720 -3.5% 15.05 US$10,836
2022-04-12 2022-04-11 PlS Planned sale

Chief Scientific Officer

Officer
2,647 -11.8%
23.05
US$61,013
2,647 -11.8% 23.05 US$61,013
2022-04-07 2022-04-06 PlS Planned sale

Chief Medical Officer

Officer
3,000 -5.3%
22.96
US$68,880
3,000 -5.3% 22.96 US$68,880
2022-03-14 2022-03-11 PlS Planned sale

Chief Scientific Officer

Officer
2,648 -11.8%
23.91
US$63,314
2,648 -11.8% 23.91 US$63,314
2022-02-28 2022-02-28 PlS Planned sale

Chief Medical Officer

Officer
3,000 -5.1%
18.79
US$56,370
3,000 -5.1% 18.79 US$56,370
2022-02-14 2022-02-11 PlS Planned sale

Chief Scientific Officer

Officer
2,647 -11.8%
22.47
US$59,478
2,647 -11.8% 22.47 US$59,478
2022-01-14 2022-01-13 PlS Planned sale

Chief Medical Officer

Officer
3,000 -4.9%
30.67
US$92,010
3,000 -4.9% 30.67 US$92,010
2022-01-13 2022-01-11 PlS Planned sale

Chief Scientific Officer

Officer
2,648 -11.8%
32.16
US$85,160
2,648 -11.8% 32.16 US$85,160
2022-01-06 2022-01-05 PlS Planned sale

Chief Medical Officer

Officer
2,000 -3.2%
40.00
US$80,000
2,000 -3.2% 40.00 US$80,000
2021-12-13 2021-12-10 PlS Planned sale

Chief Scientific Officer

Officer
2,647 -11.8%
30.88
US$81,739
2,647 -11.8% 30.88 US$81,739
2021-12-06 2021-12-03 PlS Planned sale

Chief Medical Officer

Officer
3,000 -5.0%
32.26
US$96,780
3,000 -5.0% 32.26 US$96,780
2021-12-10 2021-11-11 PlS Planned sale

Chief Scientific Officer

Officer
2,648 -11.8%
35.69
US$94,507
2,648 -11.8% 35.69 US$94,507
2021-10-19 2021-10-18 B Purchase Non-Executive Director
500 +5.7%
30.70
US$15,350
500 +5.7% 30.70 US$15,350
2021-10-15 2021-10-13 B Purchase Non-Executive Director
400 +4.8%
29.69
US$11,876
400 +4.8% 29.69 US$11,876
2021-10-14 2021-10-13 PlS Planned sale

Chief Medical Officer

Officer
3,000 -4.8%
29.69
US$89,070
3,000 -4.8% 29.69 US$89,070
2021-10-12 2021-10-11 PlS Planned sale

Chief Scientific Officer

Officer
2,647 -11.8%
30.78
US$81,475
2,647 -11.8% 30.78 US$81,475
2021-09-29 2021-09-27 S Sale Large shareholder
625 -100.0%
34.94
US$21,840
625 -100.0% 34.94 US$21,840
2021-09-29 2021-09-27 S Sale Large shareholder
1,114 -100.0%
34.97
US$38,951
1,114 -100.0% 34.97 US$38,951
2021-09-29 2021-09-27 S Sale Large shareholder
7,500 -100.0%
34.48
US$258,606
7,500 -100.0% 34.48 US$258,606
2021-09-14 2021-09-13 S Sale Large shareholder
4,788 -11.6%
35.28
US$168,942
4,788 -11.6% 35.28 US$168,942
2021-09-14 2021-09-13 S Sale Large shareholder
4,726 -6.1%
35.27
US$166,692
4,726 -6.1% 35.27 US$166,692
2021-09-14 2021-09-13 S Sale Large shareholder
4,803 -6.2%
35.25
US$169,309
4,803 -6.2% 35.25 US$169,309
2021-09-14 2021-09-10 S Sale Large shareholder
7,231 -14.9%
35.19
US$254,494
7,231 -14.9% 35.19 US$254,494
2021-09-14 2021-09-10 S Sale Large shareholder
7,320 -8.7%
35.19
US$257,572
7,320 -8.7% 35.19 US$257,572
2021-09-14 2021-09-10 S Sale Large shareholder
7,187 -8.5%
35.19
US$252,940
7,187 -8.5% 35.19 US$252,940
2021-09-13 2021-09-10 PlS Planned sale

Chief Scientific Officer

Officer
2,648 -11.8%
35.78
US$94,745
2,648 -11.8% 35.78 US$94,745